Heat Shock Protein Vaccine Trial
Title: Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. Vaccines consisting of heat shock protein-peptide complexes made from a person’s own tumor tissue may help the body build an effective immune response to kill tumor cells that may remain after surgery. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Bevacizumab reduces angiogenesis (growth of new blood vessels) in order to reduce the vascular supply of the tumor to prevent growth.
To qualify for this trial, patients must have received resection followed by chemotherapy (Temodar) and radiation at the time of their initial diagnosis, and must now have a recurrent GBM with sufficient tumor to produce the vaccine.
This is a randomized Phase II trial. Therefore, patients will be randomly assigned to one of the three following treatment groups.
1. Heat Shock Protein Vaccine + Bevacizumab given at the same time following surgery
2. Heat Shock Protein Vaccine alone, followed by Bevacizumab if progression occurs
3. Bevacizumab given alone.
Sylvester Comprehensive Cancer Center is one of only a handful of medical centers in the country offering this treatment. For more information, contact Dr. Ricardo Komotar at email@example.com.